Education
About Us
Working with TipRanks
Follow Us
Argenx Se (ARGX)
NASDAQ:ARGX
ARGX Stock Chart & Stats
$812.95
$8.96(1.38%)
At close: 4:00 PM EST
$812.95
$8.96(1.38%)
Day’s Range― - ―
52-Week Range$510.06 - $813.37
Previous CloseN/A
Volume151.62K
Average Volume (3M)351.06K
Market Cap
$49.90B
Enterprise Value$32.30B
Total Cash (Recent Filing)$3.93B
Total Debt (Recent Filing)$43.15M
Price to Earnings (P/E)38.2
Beta0.36
Next Earnings
Oct 30, 2025EPS Estimate
4.44Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)3.74
Shares Outstanding61,568,928
10 Day Avg. Volume311,939
30 Day Avg. Volume351,065
Financial Highlights & Ratios
PEG Ratio-0.12
Price to Book (P/B)6.70
Price to Sales (P/S)16.81
P/FCF Ratio-243.71
Enterprise Value/Market Cap0.65
Enterprise Value/Revenue14.08
Enterprise Value/Gross Profit21.27
Enterprise Value/Ebitda78.04
Forecast
1Y Price Target
$861.89Price Target Upside6.02% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering23
Bulls Say, Bears Say
Bulls Say
Clinical Study ResultsThe company shared details from the Phase 1b study, which showed impressive improvements in the 6-minute walk test.
Product DevelopmentARGX-119 is advancing into Phase 3 development, with the company moving fast to capitalize on its first mover advantage in congenital myasthenic syndrome.
Bears Say
Market CompetitionExperts believe Vyvgart will remain the market leader in gMG due to the lack of clear differentiation in competitor data.
Argenx Se News
ARGX FAQ
What was Argenx Se’s price range in the past 12 months?
Argenx Se lowest stock price was $510.06 and its highest was $813.37 in the past 12 months.
What is Argenx Se’s market cap?
Argenx Se’s market cap is $49.90B.
When is Argenx Se’s upcoming earnings report date?
Argenx Se’s upcoming earnings report date is Oct 30, 2025 which is in 15 days.
How were Argenx Se’s earnings last quarter?
Argenx Se released its earnings results on Jul 31, 2025. The company reported $3.74 earnings per share for the quarter, beating the consensus estimate of $3.089 by $0.651.
Is Argenx Se overvalued?
According to Wall Street analysts Argenx Se’s price is currently Undervalued.
Does Argenx Se pay dividends?
Argenx Se does not currently pay dividends.
What is Argenx Se’s EPS estimate?
Argenx Se’s EPS estimate is 4.44.
How many shares outstanding does Argenx Se have?
Argenx Se has 61,568,928 shares outstanding.
What happened to Argenx Se’s price movement after its last earnings report?
Argenx Se reported an EPS of $3.74 in its last earnings report, beating expectations of $3.089. Following the earnings report the stock price went up 11.929%.
Which hedge fund is a major shareholder of Argenx Se?
Currently, no hedge funds are holding shares in ARGX
Argenx Se Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$861.89 (6.02% Upside)
$861.89 (6.02% Upside)
Blogger Sentiment
Bullish
ARGX Sentiment 66%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 166.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.5%
Last 30 Days ▲ 6.7%
Last 30 Days ▲ 6.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
49.56%
12-Months-Change
Fundamentals
Return on Equity
24.75%
Trailing 12-Months
Asset Growth
49.60%
Trailing 12-Months
Company Description
Argenx Se
Argenx SE (ARGX) is a clinical-stage biopharmaceutical company focused on developing innovative therapies for patients with severe autoimmune diseases and cancer. The company is headquartered in Zug, Switzerland, and operates primarily in the biotechnology sector, leveraging its proprietary antibody engineering platform to create therapies that target the immune system. Argenx's core product candidates include efgartigimod, a treatment for various autoimmune conditions, and other pipeline candidates aimed at addressing unmet medical needs in both autoimmune and oncology indications.
ARGX Company Deck
ARGX Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects strong growth and expansion for VYVGART across global markets and indications, supported by financial performance and pipeline advancements. However, challenges include market dynamics in China, increased gross to net adjustments, and ongoing safety monitoring in CIDP.View all ARGX earnings summariesARGX Stock 12 Month Forecast
Average Price Target
$861.89
▲(6.02% Upside)
Technical Analysis
Ownership Overview
―
Insiders
19.71% Mutual Funds
0.13% Other Institutional Investors
79.10% Public Companies and
Individual Investors